NKX2-1 and lung adenocarcinoma: In lung adenocarcinoma, NKX2-1 (TTF-1) gain at 14q13.3 acts as a lineage-survival oncogene essential for tumor growth [25], but evidence does not support a direct relationship with immune checkpoint inhibitor response.